In a stock exchange filing on Monday, Cipla said it has entered into “definitive agreements to acquire 100% stake in Inzpera Healthsciences Limited (‘Inzpera’).” The company added, “Upon acquisition, Inzpera will become a wholly owned subsidiary of the company.”
The deal, valued at an enterprise value of Rs 120 crore, involves a total purchase consideration of approximately Rs 110.65 crore. The transaction will be completed in cash, subject to closing date adjustments, and is expected to conclude within one month from the signing of the agreement or within a mutually agreed timeline.
Strategic move to expand paediatric portfolio
Cipla said the acquisition is part of its broader strategy to build scale in the paediatric and wellness market. The company noted that integrating Inzpera’s differentiated product portfolio with Cipla’s strong distribution network and operational capabilities would help “drive growth and scalability.”Inzpera Healthsciences, incorporated in 2016, operates in the pharmaceutical industry and focuses on developing, manufacturing, and marketing innovative paediatric and wellness formulations. The firm reported revenues of Rs 26.75 crore in FY 2024–25, Rs 22.05 crore in FY 2023–24, and Rs 20.76 crore in FY 2022–23.
Cipla clarified that the deal does not fall under related party transactions and does not require any regulatory approvals for completion.
Stock performance and technical outlook
On Monday, shares of Cipla ended at Rs 1,511.60, up Rs 9.95, or 0.66%, on the BSE. However, the stock remains under pressure, down 3% over the past year and 4.6% over the last week.From a technical perspective, Cipla’s stock is trading below seven of its eight key simple moving averages, the 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, and 150-day SMAs, while holding marginally above its 200-day SMA.The Relative Strength Index (RSI) stands at 41.3, indicating the stock is neither overbought nor oversold. The Moving Average Convergence Divergence (MACD) is at -0.8 and remains below both the center and signal lines, suggesting the bearish trend may persist in the near term.
Also read | FIIs boost holdings in state-run banks in the September quarter. Is the smart money betting on a breakout?
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)